DE112005002912A5 - Pharmazeutisches Mittel umfassend Aminosäuren, Peptide, Proteine und/oder deren Bruchteile und Fragmente und deren Verwendung zur Prophylaxe und Behandlung von Defekten des Immunsystems bei Menschen und Tieren - Google Patents

Pharmazeutisches Mittel umfassend Aminosäuren, Peptide, Proteine und/oder deren Bruchteile und Fragmente und deren Verwendung zur Prophylaxe und Behandlung von Defekten des Immunsystems bei Menschen und Tieren Download PDF

Info

Publication number
DE112005002912A5
DE112005002912A5 DE112005002912T DE112005002912T DE112005002912A5 DE 112005002912 A5 DE112005002912 A5 DE 112005002912A5 DE 112005002912 T DE112005002912 T DE 112005002912T DE 112005002912 T DE112005002912 T DE 112005002912T DE 112005002912 A5 DE112005002912 A5 DE 112005002912A5
Authority
DE
Germany
Prior art keywords
prophylaxis
peptides
fractions
fragments
humans
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE112005002912T
Other languages
English (en)
Inventor
Zoser B Salama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/948,753 external-priority patent/US20060067942A1/en
Priority claimed from EP04090376A external-priority patent/EP1640012A1/de
Application filed by Individual filed Critical Individual
Publication of DE112005002912A5 publication Critical patent/DE112005002912A5/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Rolling Contact Bearings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE112005002912T 2004-09-24 2005-09-26 Pharmazeutisches Mittel umfassend Aminosäuren, Peptide, Proteine und/oder deren Bruchteile und Fragmente und deren Verwendung zur Prophylaxe und Behandlung von Defekten des Immunsystems bei Menschen und Tieren Withdrawn DE112005002912A5 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP04090376.7 2004-09-24
US10/948,753 US20060067942A1 (en) 2004-09-24 2004-09-24 Pharmaceutical agent comprising amino acids, peptides, proteins and/or fractions and fragments thereof and the use of same in the prophylaxis and treatment of immune system deficiency in humans and animals
US10/948,753 2004-09-24
EP04090376A EP1640012A1 (de) 2004-09-24 2004-09-24 Pharmazeutisches Mittel enthaltend Blutbestandteile 10 kDa und deren Verwendung zur Prophylaxe und Behandlung von Defekten des Immunsystems
PCT/DE2005/001729 WO2006032269A2 (de) 2004-09-24 2005-09-26 Pharmazeutisches mittel enthaltend blutbestandteile und oder kda und deren verwendung zur prophylaxe und behandlung von defekten des immunsystems

Publications (1)

Publication Number Publication Date
DE112005002912A5 true DE112005002912A5 (de) 2007-08-30

Family

ID=36051574

Family Applications (1)

Application Number Title Priority Date Filing Date
DE112005002912T Withdrawn DE112005002912A5 (de) 2004-09-24 2005-09-26 Pharmazeutisches Mittel umfassend Aminosäuren, Peptide, Proteine und/oder deren Bruchteile und Fragmente und deren Verwendung zur Prophylaxe und Behandlung von Defekten des Immunsystems bei Menschen und Tieren

Country Status (8)

Country Link
EP (1) EP1796695A2 (de)
JP (1) JP2008514556A (de)
AU (1) AU2005287727A1 (de)
BR (1) BRPI0517349A (de)
CA (1) CA2580192A1 (de)
DE (1) DE112005002912A5 (de)
MX (1) MX2007003489A (de)
WO (1) WO2006032269A2 (de)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1507215A (en) * 1975-08-19 1978-04-12 Green Cross Corp Processes for producing immunoregulatory preparations
HU182087B (en) * 1980-01-15 1983-12-28 Mta Kiserleti Orvostudomanyi K Process for preparing an active substance for the selective inhibition of the multiplication of normal cells and of cells in myeloide leukemia
IN161706B (de) * 1983-10-05 1988-01-16 Solco Basel Ag
RU2055589C1 (ru) * 1992-08-21 1996-03-10 Левон Никитович Мкртчян Способ получения биологически активного вещества, обладающего противоопухолевой, иммуномодулирующей и интерфероногенной активностью

Also Published As

Publication number Publication date
WO2006032269A2 (de) 2006-03-30
MX2007003489A (es) 2007-05-18
AU2005287727A1 (en) 2006-03-30
BRPI0517349A (pt) 2008-10-07
CA2580192A1 (en) 2006-03-30
EP1796695A2 (de) 2007-06-20
WO2006032269A3 (de) 2006-06-15
JP2008514556A (ja) 2008-05-08

Similar Documents

Publication Publication Date Title
DE60221051D1 (de) Herstellung von peptiden und proteinen durch anhäufung in vom endoplasmatischen reticulum abgeleiteten proteinkörpern
ATE198050T1 (de) Therapeutische anwendungen von bpi-protein- produkten zur behandlung von humaner meningococcämia
WO2004074486A3 (en) Fusion proteins of interferon alpha muteins with improved properties
NO20045521L (no) Diarylureaderivater anvendelige for behandling av proteinkinaseavhengige sykdommer
ATE389649T1 (de) Substituierte amin-derivate und deren verwendung zur behandlung von angionese-bedingten erkrankungen
ATE542801T1 (de) Zur behandlung von neoplastischen krankheiten, entzündlichen erkrankungen und erkrankungen des immunsystems geeignete 2,4-pyrimidindiamine
DE69835279D1 (de) Zusammensetzungen und verfahren zur behandlung von infektionen unter verwendung von kationischen peptiden allein oder in kombination mit antibiotika
IL171991A0 (en) Use of an interferon polypeptide in the preparation of a pharmaceutical composition for treating virus infection and a method of treating a virus-infected non human subject
DE60130791D1 (de) Amphiphile lipid-nanopartikel zur peptid- und/oder proteininkorporation
HRP20140888T1 (hr) Humana monoklonalna protutijela za humani il-4
IL222879A (en) Peptides and their use in the treatment and diagnosis of diseases and pharmaceutical preparations containing them
EP2537524A3 (de) Behandlung von T-Zell-vermittelten Krankheiten
DE69412243D1 (de) Biologisch aktive peptide aus funktionellen domaenen des bakteriziden/ die permeabilitaet erhoehenden proteins und ihre verwendung
DE50004018D1 (de) Verwendung natriuretischer peptide als antibiotisch wirksame substanzen zur behandlung von bakteriellen infektionen
ATE362928T1 (de) 2-(1h-indazol-6-ylamino)- benzamid-verbindungen als protein kinase inhibitoren und deren verwendung zur behandlung von ophthalmischen krankheiten
DE69719754D1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
DE602005013650D1 (de) Proteinhydrolysat zur behandlung von müdigkeit
ATE401400T1 (de) Antiangiogene peptide zur behandlung oder vorbeugung von endometriose
DE69838667D1 (de) Verfahren zur stabilisierung nützlicher proteine und nützliche proteinhaltige mittel
DE60303735D1 (de) Flüssiges Konzentrat zur Konservierung kosmetischer und pharmazeutischer Produkte
DK1636261T3 (da) Thrombopoietinproteiner med forbedrede egenskaber
DE112005002912A5 (de) Pharmazeutisches Mittel umfassend Aminosäuren, Peptide, Proteine und/oder deren Bruchteile und Fragmente und deren Verwendung zur Prophylaxe und Behandlung von Defekten des Immunsystems bei Menschen und Tieren
ATE361914T1 (de) Cathepsincysteinproteaseinhibitoren und deren verwendung zur behandlung von entzündungen und immunerkrankungen
ZA200703237B (en) Pharmaceutical agents comprising blood components <10 KDA and their use for prophylaxis and treatment of defects of the immune system
WO2001007479A3 (en) Fragments of cellular prion protein and methods useful in the diagnosis and treatment of prion diseases

Legal Events

Date Code Title Description
8139 Disposal/non-payment of the annual fee